IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

  1. April 24, 2024

    Motley Rice, Morgan & Morgan Among Ozempic MDL Leaders

    The Pennsylvania federal judge overseeing multidistrict litigation over alleged risks associated with Ozempic and similar drugs has appointed lawyers from Motley Rice LLC, Morgan & Morgan PA and six other firms to leadership roles, according to an order issued Tuesday.

  2. February 05, 2024

    Ozempic Injury Suits Consolidated In Eastern Pa. MDL

    The Judicial Panel on Multidistrict Litigation has moved 55 MDL cases over Ozempic and similar drugs to the Eastern District of Pennsylvania, centralizing the litigation that claims Novo Nordisk A/S and Eli Lilly & Co. failed to warn patients about the risks associated with the class of drug.